{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T02:27:14Z","timestamp":1771468034025,"version":"3.50.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,8,27]],"date-time":"2010-08-27T00:00:00Z","timestamp":1282867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2010,8,27]],"date-time":"2010-08-27T00:00:00Z","timestamp":1282867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1007\/s10637-010-9525-0","type":"journal-article","created":{"date-parts":[[2010,8,26]],"date-time":"2010-08-26T02:22:48Z","timestamp":1282789368000},"page":"376-381","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients"],"prefix":"10.1007","volume":"30","author":[{"given":"Romain","family":"Coriat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Mir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anatole","family":"Cessot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Brezault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanislas","family":"Ropert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Philippe","family":"Durand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wulfran","family":"Cacheux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanislas","family":"Chaussade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Goldwasser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,8,27]]},"reference":[{"issue":"Suppl 3","key":"9525_CR1","doi-asserted-by":"publisher","first-page":"S206","DOI":"10.1016\/S1590-8658(10)60507-5","volume":"42","author":"H Nordenstedt","year":"2010","unstructured":"Nordenstedt H, White DL, El-Serag HB (2010) The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 42(Suppl 3):S206\u2013S214","journal-title":"Dig Liver Dis"},{"key":"9525_CR2","doi-asserted-by":"crossref","unstructured":"(1995) A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d\u2019Etude et de Traitement du Carcinome Hepatocellulaire. N Engl J Med 332:1256\u20131261","DOI":"10.1056\/NEJM199505113321903"},{"key":"9525_CR3","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1002\/hep.510270617","volume":"27","author":"J Bruix","year":"1998","unstructured":"Bruix J, Llovet JM, Castells A, Montana X, Bru C, Ayuso MC, Vilana R, Rodes J (1998) Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 27:1578\u201383","journal-title":"Hepatology"},{"key":"9525_CR4","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1002\/hep.510270616","volume":"27","author":"JM Llovet","year":"1998","unstructured":"Llovet JM, Bruix J, Fuster J, Castells A, Garcia-Valdecasas JC, Grande L, Franca A, Bru C, Navasa M, Ayuso MC, Sole M, Real MI, Vilana R, Rimola A, Visa J, Rodes J (1998) Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power. Hepatology 27:1572\u20131577","journal-title":"Hepatology"},{"key":"9525_CR5","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378\u201390","journal-title":"N Engl J Med"},{"key":"9525_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1046\/j.1365-2036.1998.00286.x","volume":"12","author":"P Mathurin","year":"1998","unstructured":"Mathurin P, Rixe O, Carbonell N, Bernard B, Cluzel P, Bellin MF, Khayat D, Opolon P, Poynard T (1998) Review article: Overview of medical treatments in unresectable hepatocellular carcinoma\u2014an impossible meta-analysis? Aliment Pharmacol Ther 12:111\u201326","journal-title":"Aliment Pharmacol Ther"},{"key":"9525_CR7","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099\u2013109","journal-title":"Cancer Res"},{"key":"9525_CR8","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1002\/cncr.11869","volume":"98","author":"J Taieb","year":"2003","unstructured":"Taieb J, Bonyhay L, Golli L, Ducreux M, Boleslawski E, Tigaud JM, de Baere T, Mansourbakht T, Delgado MA, Hannoun L, Poynard T, Boige V (2003) Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules. Cancer 98:2664\u201370","journal-title":"Cancer"},{"key":"9525_CR9","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1056\/NEJMoa032709","volume":"350","author":"T Andre","year":"2004","unstructured":"Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343\u20132351","journal-title":"N Engl J Med"},{"key":"9525_CR10","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/00000421-200204000-00021","volume":"25","author":"J Alexandre","year":"2002","unstructured":"Alexandre J, Tigaud JM, Gross-Goupil M, Gornet JM, Romain D, Azoulay D, Misset JL, Goldwasser F (2002) Combination of topotecan and oxaliplatin in inoperable hepatocellular cancer patients. Am J Clin Oncol 25:198\u2013203","journal-title":"Am J Clin Oncol"},{"key":"9525_CR11","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1002\/cncr.22532","volume":"109","author":"S Louafi","year":"2007","unstructured":"Louafi S, Boige V, Ducreux M, Bonyhay L, Mansourbakht T, de Baere T, Asnacios A, Hannoun L, Poynard T, Taieb J (2007) Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer 109:1384\u201390","journal-title":"Cancer"},{"key":"9525_CR12","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1093\/annonc\/mdh095","volume":"15","author":"L Rubbia-Brandt","year":"2004","unstructured":"Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, Dousset B, Morel P, Soubrane O, Chaussade S, Mentha G, Terris B (2004) Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15:460\u20136","journal-title":"Ann Oncol"},{"key":"9525_CR13","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1200\/JCO.2009.23.1407","volume":"28","author":"A de Gramont","year":"2010","unstructured":"de Gramont A, Hubbard J, Shi Q, O\u2019Connell MJ, Buyse M, Benedetti J, Bot B, O\u2019Callaghan C, Yothers G, Goldberg RM, Blanke CD, Benson A, Deng Q, Alberts SR, Andre T, Wolmark N, Grothey A, Sargent D (2010) Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. J Clin Oncol 28:460\u2013465","journal-title":"J Clin Oncol"},{"key":"9525_CR14","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1200\/JCO.2005.01.3441","volume":"24","author":"GK Abou-Alfa","year":"2006","unstructured":"Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:4293\u2013300","journal-title":"J Clin Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9525-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-010-9525-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9525-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9525-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T05:07:20Z","timestamp":1678511240000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-010-9525-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,27]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["9525"],"URL":"https:\/\/doi.org\/10.1007\/s10637-010-9525-0","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,27]]},"assertion":[{"value":"15 July 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}